PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32705171-9	2020	PDTC treatment and p53 knockdown significantly decreased matrix metallopeptidase (MMP)-3, MMP-13, metallopeptidases with thrombospondin type 1 motif (ADAMTS)-4 and ADAMTS-5 expression levels, and increased aggrecan and collagen type II expression levels in IL-1beta-stimulated cells.	pyrrolidine dithiocarbamic acid	0-4	matrix metallopeptidase 13	Homo sapiens	90-96	
34463587-11	2021	Furthermore, PDTC decreased IL-1beta-induced chondrocyte apoptosis with the upregulated COL1A1, COL2A1, COL10A1 and ACAN, as well as the down-regulated MMP1, MMP13, COX2, iNOS, IL-6, TNF-alpha, NO and PGE2, which was reversed by A20 siRNA.	pyrrolidine dithiocarbamic acid	13-17	matrix metallopeptidase 13	Homo sapiens	158-163	
19379726-0	2009	Pyrrolidine dithiocarbamate, a NF-kappaB inhibitor, upregulates MMP-1 and MMP-13 in IL-1beta-stimulated rheumatoid arthritis fibroblast-like synoviocytes.	pyrrolidine dithiocarbamic acid	0-27	matrix metallopeptidase 13	Homo sapiens	74-80	
12009331-8	2002	NF-kappaB inhibitor, pyrrolidine dithiocarbamate yielded 83-84% reduction of MMP-3 and 38-55% for MMP-13 in human chondrocytes.	pyrrolidine dithiocarbamic acid	21-48	matrix metallopeptidase 13	Homo sapiens	98-104